Search results
11 lis 2020 · Sarcoidosis is a multi-systemic granulomatous disease. Affected individuals can show spontaneous healing, develop remission with drug treatment within 2 years, or become chronically ill. Our main goal was to identify features that are related to prognosis.
Methotrexate. Methotrexate is one of the most commonly used corticosteroid-sparing therapies for sarcoidosis, due to its effectiveness, low cost and, at the dosages used to treat sarcoidosis, relatively low risk of side effects compared to other cytotoxic agents. The drug can be given orally or sub-cutaneously.
29 lis 2022 · Sarcoidosis is a heterogeneous disease with variable organ involvement, disease course, and response to treatment. We offer an angle on when and how to treat, and provide an overall roadmap for managing sarcoidosis.
Prognosis is variable and depends on epidemiologic factors, mode of onset, initial clinical course, and specific organ involvement. The optimal treatment for sarcoidosis remains unclear, but...
25 lis 2020 · Sarcoidosis is a multi-systemic granulomatous disease. Affected individuals can show spontaneous healing, develop remission with drug treatment within 2 years, or become chronically ill. Our...
Treatment usually is indicated in symptomatic patients. First-line treatment is corticosteroids. Prognosis is excellent for limited disease but poor for more advanced disease. Sarcoidosis most commonly affects people aged 20 to 40 years but occasionally affects children and older adults.
Sarcoidosis is a systemic inflammatory granulomatous disease mainly affecting the lungs and thoracic lymph nodes. In a previous article in this journal, we reviewed emerging aspects of diagnosis and monitoring of the disease. This narrative paper aims to review and update sarcoidosis management.
